Denmark's Ascendis Pharma has raised €17.6 million ($25.84 million) in its first round of financing. The round was led by Sofinnova Partners. Ascendis plans to use the money to broaden the company's pipeline and to position itself in the space of lifecycle management of marketed drugs.
- check out the release for more details
ALSO: Cempra Pharmaceuticals, which is developing anti-infective drugs--has garnered $10 million in Series B funding. Backers include Aisling Capital, Intersouth Partners, Optimer Pharmaceuticals Inc. and banker I. Wistar Morris III. Report
PLUS: Arcion Therapeutics has raised $8.85 million in Series A funding. The company is focused on pain management treatments. Report